You are here: Industry Insights > haemophilia A

News List

Blood Disorders Pipeline Database 2018: Neutropenia, Sickle-cell Disorders, Thalassemia, Iron deficiency anemia, Haemophilia A, and Haemophilia B biospace
April 19, 2018
Blood Disorders Pipeline Highlights Database - 2018, provides most up-to-date information on key pipeline products in the global Blood Disorders Drug market.
Seven medicines leap closer to EU approval pharmatimes
January 30, 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Roche’s Hemlibra reduces bleeds in haemophilia A patients pharmatimes
November 21, 2017
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
FDA accepts Roche’s BLA for emicizumab to treat Haemophilia A expressbpd
August 28, 2017
The US Food and Drug Administration (FDA) has accepted Roche’s biologics licence application (BLA) and granted priority review for emicizumab prophylaxis (preventative) to treat patients with haemophilia A with factor VIII inhibitors.
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Jour worldpharmanews
July 13, 2017
Roche today announced that data from HAVEN 1, a phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with haemophilia A with inhibitors, were published in The New England Journal of Medicine (

Previous page 1 2 Next page